



12th International Congress on **LUNG TRANSPLANTATION**

Paris, september 15-16, 2016

Union Internationale des Chemins de Fer
16, rue Jean Rey, Paris 15^e



Program

Thursday, September 15 2016

9.00-12.30 a.m.

Room Louis Armand

Update of Antibody Mediated Rejection

Chairpersons : Pr Tom Waddell (Toronto), Pr Geert Verleden (Leuven)

9.00

Wellcome

Antoine Roux, Edouard Sage (Suresnes, France)

9.10

AMR: A clinical consensus?

Deborah J. Levine (San Antonio, USA)

9.40

Pathology of AMR: a unified view?

Fiorella Calabrese (Padova, Italy)

10-00 – 10h20 COFFEE BREAK

10.20

De Novo DSA: What does it mean and what do we do?

Jussi Tikkanen (Toronto, Canada)

10.45

O1

Intrapulmonary anti HLA donor specific antibodies (DSA): Correlation with antibody mediated rejection (AMR) in lung transplantation.

S. Hirschi, J. Olagne, A. Essaydi, T. Degot, A. Schuller, S. Caillard Ohlmann, R. Kessler, A. Parissiadis, MP. Chenard, F. Calabrese (Strasbourg, France)

10.57

O2

Persistence of de novo donorspecific HLA-antibodies increases the risk of lung allograft dysfunction

T. Kauke, M. Schmitzer, N. Kneidinger, C. Neurohr, V. Von Dossow, G. Preissler, R. Schramm, H. Winter (Munich, Germany)

11.09

Anti HLA: What role in BOS and RAS development
Robin Vos (Leuven, Belgium)

11.35

Treatment of established AMR.
Antoine Roux (Suresnes, France)

10.00-10.20 a.m. Break

10.20-12.30 a.m.

Room List

Oral communications

Chairpersons: Dr Mark Greer (Hanover), Dr Benoit Douvry (Suresnes)

10.20

03

Induction or no induction after lung transplantation? Vienna experience.
A. Benazzo, S. Schwarz, G. Muraközy, C. Lambers, G. Lang, S. Taghavi, W. Klepetko, P. Jaksch (Vienna, Austria)

10.32

04

ExtraCorporeal Membrane Oxygenation in Lung Transplantation – Causes and Complications.
J. Fessler, M. Fischler, M. Le Guen (Suresnes, France)

10.44

05

Ten-Year Experience with Venous-Arterial Extracorporeal Membrane Oxygenation during Double Lung Transplantation.
L.J. Ceulemans, J. De Beule, A. Neyrinck, M. Schetz, W. Coosemans, H. Decaluwé, P. De Leyn, L. Depypere, P. Nafteux, H. Van Veer, B. Meyns, P. Herijgers, F. Rega, B. Meuris, R. Vos, L. Dupont, M. Delcroix, G.M. Verleden, D. Van Raemdonck (Leuven, Belgium)

10.56

06

Veno-arterial Extracorporeal Life Support (ECLS) After Bilateral Lung and Heart-Lung Transplantation for Pulmonary Hypertension.
T. Kortchinsky, S. Mussot, S. Rezaiguia-Delclaux, M. Artiguanave, E. Fadel, F. Stephan (Le Plessis Robinson)

11.08

07

Altered Long Term T-Cell Reactions in Patients Undergoing Extracorporeal Membrane Oxygenation Prior to Lung Transplantation.
N. Strobl, H. Winter, G. Warnecke, E. Noessner, A. Knoefel, T. Kauke, R. Schramm, R. Hatz, A. Haverich, G. Preissler (Munich, Germany)

11.20

08

Comparison of off-pump lung transplantation versus the use of cardiopulmonary bypass: a single centre experience.

A. Page, T. Devine, S. Messer, C. Barbero, P. Catarino, J. Parmar (Cambridge, UK)

11.32

O9

Increasing lung donor pool using Ex-Vivo Lung Perfusion (EVLP) technology should decrease the cost of lung transplantation.

C. Keller, T. Gonwa, J. Naessens, L. While, M. Rucci, S. Visscher, R. Daly (Jacksonville, USA)

11.44

O10

Bilateral lung retrieval from a 6 weeks old baby - the youngest donor in the UK.

E. Pavlushkov, N. Muthialu, H. Spencer, C. Ellis, B. Davis, S. Claydon, H. Garrido, M. Berman (Cambridge, UK)

11.56

O11

GvHD posttransplant pulmonary for histiocytosis.

F. Garaix, C. Galambrun, N. Stremler, M. Tsimaratos (Marseille, France)

12.08

O12

Hyperthyroidism after heart transplantation.

M. Barten, S. Schmidt, M. Rybczynski, FM. Wagner, H. Reichenspurner (Hamburg, Germany)

12.45 a.m.-1.45 p.m.

Room Louis Armand

Antibody mediated rejection

**symposium sponsored by One Lambda – A Thermo Fisher Scientific Brand
Chairpersons : Ramsey R. Hachem (Saint-Louis, USA), Antoine Roux (Suresnes)**

12.45

Multidimensional approach of Antibodies where are we?

Carmen Lefaucheur (Paris, France)

1.05

Antibody Mediated Rejection ISHLT consensus: consequences for the future of LT research.

Ramsey R. Hachem (Saint-Louis, USA)

1.25

Global risk stratification in solid organ transplantation.

Alexandre Loupy (Paris France)

2.00-4.00 p.m.

Room Louis Armand

Hot Topics in Lung Transplantation II

Chairpersons : Pr Christiane Knoop (Brussels), Pr Peter Jaksch (Vienna)

2.00

Biomarkers in PAH and timing of transplantation

Laurent Savale (Le Kremlin-Bicêtre, France)

2.20

New approaches of the perioperative management of lung transplant patients for PAH

Olaf Mercier (Le Plessis Robinson, France)

2.40

Cancer-related death after lung transplantation: the new first cause of mortality
Tom Waddell (Toronto, Canada)

3.00

How should we screen solid organ recipient for cancer?
Jacques Dantal (Nantes, France)

3.20

Retransplantation: Ethics and optimal management
Shaf Keshavjee (Toronto, Canada)

4.00-4.20 p.m. Break

4.20-6.00 p.m.

Room Louis Armand

Antimicrobials for Improving Outcomes

Chairpersons : Pr Jens Gottlieb (Hanover), Dr Clément Picard (Suresnes)

4.20

Can we prevent CLAD with anti-infectives?
Mark Greer (Hannover, Germany)

4.40

Reducing CLAD with ALN-RSV01
Jens Gottlieb (Hannover, Germany)

5.00

O13

Streptococcus pneumoniae in lung transplantation recipients: colonization, infection, vaccination.

C. Picard, E. Farfour, L. Beaumont, AM. Hamid, B. Douvry, S. De Miranda, D. Grenet, G. Trebbia, F. Parquin, A. Roux (Suresnes, France)

5.12

EBV Lymphoproliferation
Lionel Galicier (Paris, France)

5.32

Anti-fungals in lung transplantation – state of the art
Eliane Billaud (Paris, France)

2.00-6.00 p.m.

Room List

Chronic Lung Allograft Dysfunction

Chairpersons : Pr Andrew Fisher (Newcastle), Dr Antoine Roux (Suresnes)

2.00

The pathophysiology of CLAD development and the role of colonization
Andrew Fisher (Newcastle, UK)

2.20

The microbiome in CLAD: results from the Sysclad study
John-David Aubert (Lausanne, Switzerland)

2.40

O14

Characterization of a B lymphocyte signature predictive of chronic lung allograft dysfunction: COLT study.

C. Brosseau, M. Durand, E. Durand, J. Loy, P. Lacoste, P. Royer, S. Brouard, A. Magnan (Nantes, France)

2.52

What did we learn from the COLT / SysCLAD study?

Adrien Tissot (Nantes, France)

3.12

Transcriptome analysis in Lung Transplantation

Pierre-Joseph Royer (Grenoble, France)

3.32

O15

Gastroesophageal Reflux Disease after Lung Transplantation: Potential Risk Factors, Aetiology and long term Outcome.

B. Schmack, A. Sabashnikov, A. Padukone, A. Weymann, P. Mohite, M. Carby, A. Reed, AR. Simon, AF. Popov, S. Soresi (London, UK)

3.45

Imaging in CLAD: what's new?

Stijn E. Verleden (Leuven, Belgium)

4.05-4.20 p.m. Break

4.20

DEBATE : Azithromycin treatment after lung LTx:

- Prevention is the best option – *Robin Vos (Leuven, Belgium)*
- Treatment is the best option – *Paul Corris (Newcastle upon Tyne, UK)*

4.50

New therapies: Extra Corporeal Photophoresis for CLAD

Peter Jaksch (Vienna, Austria)

5.10

New therapies: Extra Corporeal Photopheresis for DSA

Ramsey Hachem (St Louis, USA)

5.30

New therapies: Anti-fibrotics

Geert Verleden (Leuven, Belgium)

Friday, September 16 2016

8.00-12.30 a.m.

Room Louis Armand

Hot Topics in Lung Transplantation I – Focus on Recipient Selection

Chairpersons : Pr Edward Cantu (Philadelphia), Pr Gabriel Thabut (Paris)

8.00

Update on recipient selection guidelines

John Dark (Newcastle, UK)

8.20

O16

Pediatric Lung Transplantation: 25 years of experience.

R. Waseda, P. Jaksch, G. Muraközy, S. Gruber, C. Lambers, A. Benazzo, Z. Szepfalusi, E. Nachbauer, W. Klepetko (Vienna, Austria)

8.32

017

Lung-first versus liver-first: a new dilemma in combined organ transplantation.

L.J. Ceulemans, R. Vos, G.M. Verleden, J. Pirenne, A. Neyrinck, D. Van Raemdonck (Leuven, Belgium)

8.45

Lung Transplantation in patients over 70

Edward Cantu (Philadelphia, USA)

9.05

Scleroderma: to transplant or not?

Jérôme Le Pavec (Le Plessis Robinson, France)

9.25

Lung transplantation after stem cell transplantation

Mark Greer (Hannover, Germany)

9.45

Telomerase mutations and lung transplantation

Raphaël Borie (Paris, France)

10.05-10.20 a.m. Break

10.20

Role of adherence in lung transplantation.

Fabienne Dobbels (Leuven, Belgium)

10.40

DEBATE: A lung allocation scoring system should be introduced in all countries?

- Pro: *Jens Gottlieb (Hannover, Germany)*
- Con: *Gabriel Thabut (Paris, France)*

11.20

Awake ECMO as bridge to lung transplant

Alberto Benazzo (Vienna, Austria)

11.40

Pulmonary fibrosis - why is that more difficult and what can we do about it

Geert Verleden (Leuven, Belgium)

8.00-10.00 a.m.

Room List

The Donor Pool: Making the most of what we've got til we get to the future

Chairpersons : Pr Dirk Van Raemdonck (Leuven), Dr François Parquin (Suresnes)

8.00

Management of the Potential Lung Donor

Eduardo Minambres (Santander, Spain)

8.25

What is a marginal donor nowadays?

Tom Waddell (Toronto, Canada)

8.50

O18

Lung transplantation from donors after previous cardiac surgery: ideal graft in marginal donor?

A. Palleschi, A. Mariolo, M. Montoli, P. Mendogni, D. Tosi, L. Morlacchi, P. Tarsia, F. Valenza, M. Nosotti (Milan, Italy)

9.02

Lung Donation after Euthanasia

Dirk van Raemdonck (Leuven, Belgium)

9.27

Lung Donation following Hanging

Edouard Sage (Suresnes, France)

10.00-10.20 a.m. Break

10.20-12.30 a.m.

Room List

Oral communications

Chairpersons : Dr Robin Vos (Leuven), Dr Elise Cuquemelle (Suresnes)

10.20

O19

SCEDO-LUNG: International practice survey on *Scedosporium* colonization and infection in lung transplant recipients.

B. Rammaert, J. Le Pavec, O. Lortholary (Paris, France)

10.32

O20

Acute RSV infection in lung transplantation recipients: factors associated with a decrease in lung function.

H. Lafoeste, C. Picard, E. Farfour, L. Beaumont, L. Zemoura, B. Douvry, S. De Miranda, D. Grenet, AM. Hamid, A. Roux (Suresnes, France)

10.44

O21

Growth and pubertal onset after lung transplant in children with cystic fibrosis.

S. Abdelkefi, R. Guillemain, V. Boussaud, F. Barthes-Lepimpec, I. Sermet-Gaudelus (Paris, France)

10.56

O22

Lung Retransplantation in Argentina: Single Center Experience.

A. Bertolotti, R. Ahumada, JM. Osses, G. Wagner, J. Caneva, G. Parrilla, M. Candiotti, RR. Favaloro (Buenos Aires, Argentina)

11.08

O23

Basiliximab for the treatment of acute cellular rejection after lung transplantation: a retrospective cohort study.

AM. Rabain, A. Senechal, S. Sanchez, F. Thivolet-Bejui, JF. Mornex (Lyon)

11.20

O24

Immunomodulatory effects of extracorporeal photopheresis are dependent on rejection status – a pilot study.

M. Barten, J. Garbade, H. Reichenspurner, FW. Mohr, C. Oelschner, MT. Dieterlen (Hamburg, Germany)

11.32

O25

TGF-B1 in restrictive CLAD: is it important?

S. Verleden, A. Sacreas, H. Bellon, E. Vandermeulen, T. Heigl, D. Van Raemdonck, G. Verleden, R. Vos, B. Vanaudenaerde (Leuven, Belgium)

11.44

O26

Analysis of the regulatory T lymphocytes profile as predictive biomarker of the lung allograft chronic dysfunction in Humans.

M. Durand, P. Lacoste, C. Brosseau, E. Durand, J. Loy, S. Brouard, A. Magnan (Nantes, France)

11.56

O27

Security and usefulness of everolimus (ImTOR) associated with low tacrolimus dose to preserve kidney function in pediatrics lung.

F. Garaix, E. Sampol, N. Stremler, M. Tsimaratos (Marseille, France)

12.08

O28

Autofluorescence bronchoscopy as innovative marker of airway complications after lung transplantation.

L. Rosso, R. Carrinola, A. Palleschi, I. Righi, G. Invernici, M. Cattaneo, M. Pappalettera, F. Briganti, V. Rossetti, M. Nosotti (Milan, Italy)

12.20

O29

Novel Approach for the Treatment of GERD after Lung Transplantation: Electrical Stimulation of the Lower Esophageal Sphincter.

A. Bertolotti, A. Nieponice, R. Ahumada, A. Badaloni, JM. Osses, C. Bilder, G. Wagner, RR. Favaloro (Buenos Aires, Argentina)

12.30 a.m.-2.00 p.m. Break

2.00-4.30 p.m.

Room Louis Armand

Therapeutic Approaches: Old, New and Future

Chairpersons : Pr Paul Corris (Newcastle), Pr Denis Glotz (Paris)

2.00

Tolerance : definition and how to detect it ?

Sophie Brouard (Nantes, France)

2.20

Complications with CNI and how to deal with them?

Jussi Tikkanen (Toronto, Canada)

2.40

Shifting tacrolimus from BID to OD

- A nephrologist's view *Dany Anglicheau (Paris, France)*
- A pulmonologist view *Christiane Knoop (Brussels, Belgium)*

3.10

Review of induction therapy

Paul Corris (Newcastle upon Tyne, UK)

3.30
Anticomplement therapy in kidney transplantation
Denis Glotz (Paris, France)

3.50
Experience of adoptive Treg/Dendritic cells
Julien Zuber (Paris, France)

2.00-4.05 p.m.

Room List

EVLP – the end of PGD?

Chairpersons : Pr Shaf Keshavjee (Toronto), Dr Edouard Sage (Suresnes)

2.00
Pathophysiology and classification of PGD
Edward Cantu (Philadelphia, USA)

2.20
Logistical EVLP: the standard lung for transport and logistics
Anne Olland (Strasbourg, France)

2.40
EVLP to sterilize lungs
Andrew J. Fisher (Newcastle, UK)

3.00
Drug treatment during EVLP to reduce PGD
Dirk Van Raemdonck (Leuven, Belgium)

3.20
O30
Cell-free Hemoglobin: A new Thérapeutic Target for Prevention of Primary Graft Dysfunction?
C.M. Shaver, N. Wickersham, J.B. Mcneil, H. Nagata, J.L. Kuck, J.A. Bastarache, L.B. Ware (Nashville, USA)

3.32
O31
Association of Long Pentraxin-3 with Pulmonary Hypertension and Primary Graft Dysfunction in Lung Transplant Recipients.
J. Diamond, K. Ramphal, E. Cantu, M. Porteous, S. Palmer, P. Shah, M. Crespo, C. Hage, A. Weinacker, Y. Suzuki, V. Lama, K. Wille, L. Ware, S. Borade, L. Snyder, J. Orens, J. Christie, S. Kawut (Philadelphia, USA)

3.45
Genetically modified lungs and the future of EVLP
Shaf Keshavjee (Toronto, Canada)

POSTERS

P1
Non-Tuberculous Mycobacteria infection and lung transplantation in Cystic Fibrosis: A worldwide survey of clinical practice.
A. Tissot, M. Thomas, P. Corris, M. Brodlie (Newcastle, UK)

P2

Heart rate variability in bilateral lung transplant recipients.

T. Fontolliet, P. Gianella, V. Pichot, P. M. Soccal, G. Ferretti, F. Lador (Geneva, Switzerland)

P3

Lung transplant projected commercial claim costs for 2016 in the United States.

S. George, A. Holland, S. Bentley, E. Claxton (Tampa, USA)

P4

Conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation - Hungarian experiences.

N. Eszes, V. Müller, Z. Kováts, E. Csiszér, Z. Süttő, K. Czebe, G. Muraközi, G. Lang, G. Losonczy, A. Bohács (Budapest, Hungary)

P5

Secondary pulmonary alveolar proteinosis after lung transplantation: A series with review of literature.

Q. Philippot, R. Borie, A. Cazes, M.P. Debray, D. Sroussi, C. Dupin, G. Dauriat, G. Jebrak, Y. Castier, P. Mordant, G. Thabut, H. Mal, O. Brugière (Paris, France)